Longs, Guess what? Arena is preparing to pick-up its insomnia research VERY VERY SOON!
DIARYL AND ARYLHETEROARYL UREA DERIVATIVES AS MODULATORS OF THE 5-HT2A SEROTONIN RECEPTOR USEFUL FOR THE PROPHYLAXIS AND TREATMENT OF DISORDERS RELATED THERETO
United States Patent Application 20130237541
Just as I suspected the company was not done with its insomnia research and is aggressively moving to reinstate an improved version back into the pipeline. -sv
Investors. Combo-chemistry coming your way! "The present invention also relates to the method of prophylaxis or treatment of 5-HT2A serotonin receptor mediated disorders in combination with a dopamine D2 receptor antagonist such as haloperidol, administered separately or together." -sv